Polymer-free sirolimus-eluting stent use in Europe and Asia: Ethnic differences in demographics and clinical outcomes

Autoři: Florian Krackhardt aff001;  Matthias Waliszewski aff001;  Wan Azman Wan Ahmad aff003;  Viktor Kočka aff004;  Petr Toušek aff004;  Bronislav Janek aff005;  Milan Trenčan aff006;  Peter Krajči aff006;  Fernando Lozano aff007;  Koldobika Garcia-San Roman aff008;  Imanol Otaegui Irurueta aff009;  Bruno Garcia del Blanco aff009;  Lucie Wachowiak aff010;  Victoria Vilalta del Olmo aff011;  Eduard Fernandez Nofrerías aff011;  Myung Ho Jeong aff012;  Byung-Chun Jung aff013;  Kyu-Rock Han aff014;  Christophe Piot aff015;  Laurent Sebagh aff016;  Jérôme Rischner aff017;  Michel Pansieri aff018;  Matthias Leschke aff019;  Tae Hoon Ahn aff020
Působiště autorů: Department of Internal Medicine and Cardiology, Charité–Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany aff001;  Medical Scientific Affairs, B.Braun Melsungen AG, Berlin, Germany aff002;  University Malaya Medical Centre, Kuala Lumpur, Malaysia aff003;  University Hospital Královské Vinohrady Prague, Czech Republic aff004;  IKEM Prague, Czech Republic aff005;  SÚSCCH, a.s. Banská Bystrica, Slovak Republic aff006;  Hospital General Universitario de Ciudad Real, Ciudad Real, Spain aff007;  Hospital Universitario de Cruces, Bilbao, Spain aff008;  Hospital Universitari Vall d’Hebron Barcelona, Spain aff009;  Medical Scientific Affairs, B.Braun France, Saint-Cloud, France aff010;  Hospital Universitari Germans Trias i Pujol, Badalona, Spain aff011;  Chonnam National University, Gwangju, South Korea aff012;  Daegu Fatima Hospital, Daegu, South Korea aff013;  Kangdong Sacred Heart Hospital, Kangdong, South Korea aff014;  Clinique du Millénaire, Montpellier, France aff015;  Clinique Turin, Paris, France aff016;  Hôpital Albert Schweitzer Colmar, France aff017;  Centre Hospitalier d'Avignon, Avignon, France aff018;  Städtische Kliniken Esslingen, Esslingen, Germany aff019;  Gachon University Gil Medical Center, Incheon, South Korea aff020
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0226606



The objective of this study was to assess regional and ethnic differences in an unselected patient population treated with polymer-free sirolimus-eluting stents (PF-SES) in Asia and Europe.


Two all-comers observational studies based on the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were combined for data analysis to assure sufficient statistical power. The primary endpoint was the accumulated target lesion revascularization (TLR) rate at 9–12 months.


Of the total population of 7243 patients, 44.0% (3186) were recruited in the Mediterranean region and 32.0% (2317) in central Europe. The most prominent Asian region was South Korea (17.6%, 1274) followed by Malaysia (5.7%, 413). Major cardiovascular risk factors varied significantly across regions. The overall rates for accumulated TLR and MACE were low with 2.2% (140/6374) and 4.4% (279/6374), respectively. In ACS patients, there were no differences in terms of MACE, TLR, MI and accumulated mortality between the investigated regions. Moreover, dual antiplatelet therapy (DAPT) regimens were substantially longer in Asian countries even in patients with stable coronary artery disease as compared to those in Europe.


PF-SES angioplasty is associated with low clinical event rates in all regions. Further reductions in clinical event rates seem to be associated with longer DAPT regimens.

Klíčová slova:

Antiplatelet therapy – Coronary stenting – diabetes mellitus – Ethnic epidemiology – Europe – Lesions – Malaysia – South Korea


1. Ananthakrishna R, Kristanto W, Liu L, Chan SP, Loh PH, Tay EL, et al. Incidence and predictors of target lesion failure in a multiethnic Asian population receiving the SYNERGY coronary stent: A prospective all-comers registry. Catheter Cardiovasc Interv. 2018;92:1097–1103. doi: 10.1002/ccd.27577 29513378

2. Klomp M, Damman P, Beijk MA, Tan KH, Balian V, de Luca G, et al.; e-HEALING investigators. Differences in cardiovascular risk factors and clinical outcomes between Western European and Southeast Asian patients treated with the Genous Bio-engineered R stent: an e-HEALING worldwide registry substudy. Coron Artery Dis. 2012;23:271–277. doi: 10.1097/MCA.0b013e328351aaed 22473083

3. Pepe M, Biondi-Zoccai G, Corcione N, Nestola PL, Ferraro P, Morello A, et al. Comparative Effectiveness and Safety of Polymer-Free Biolimus-Eluting Stent and Durable Polymer Everolimus-Eluting Stent in All-Comer Patients Who Underwent Percutaneous Coronary Interventions. Am J Cardiol. 2019 Apr 23. pii: S0002–9149(19)30454-0. doi: 10.1016/j.amjcard.2019.04.015 31103132

4. Jensen LO, Thayssen P, Maeng M, Ravkilde J, Krusell LR, Raungaard B, et al. Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.Circ Cardiovasc Interv. 2016;9(7). pii: e003610. doi: 10.1161/CIRCINTERVENTIONS.115.003610 27412869

5. Yeh RW, Silber S, Chen L, Chen S, Hiremath S, Neumann FJ, et al. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program. JACC Cardiovasc Interv. 2017;10: 247–254. doi: 10.1016/j.jcin.2016.11.004 28109872

6. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–260. doi: 10.1093/eurheartj/ehx419 28886622

7. Bae JS, Ahn JH, Tantry US, Gurbel PA, Jeong YH. Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians? Curr Vasc Pharmacol. 2018;16:459–476. doi: 10.2174/1570161116666180117103238 29345591

8. Krackhardt F, Kočka V, Waliszewski MW, Utech A, Lustermann M, Hudec M, et al. Polymer-free sirolimus-eluting stents in a large-scale all-comers population. Open Heart. 2017;4:e000592. doi: 10.1136/openhrt-2017-000592 28761678

9. Krackhardt F, Rosli MA, Leschke M, Schneider A, Sperling C, Heang TM, et al. Propensity score matched all comers population treated with ultra-thin strut bare metal and sirolimus-probucol coated drug-eluting stents of identical stent architecture. Catheter Cardiovasc Interv. 2018;91:1221–1228. doi: 10.1002/ccd.27306 28944613

10. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al.; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344–2351 doi: 10.1161/CIRCULATIONAHA.106.685313 17470709

11. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials. Circulation. 2011;123:2736–2747. doi: 10.1161/CIRCULATIONAHA.110.009449 21670242

12. Sperling C, Waliszewski MW, Kherad B, Krackhardt F. Comparative preclinical evaluation of a polymer-free sirolimus-eluting stent in porcine coronary arteries. Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719826335. doi: 10.1177/1753944719826335 30803407

13. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–2619. doi: 10.1093/eurheartj/ehu278 25173339

14. Wöhrle J, Zadura M, Möbius-Winkler S, Leschke M, Opitz C, Ahmed W, et al. SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol. 2012;60:1733–1738. doi: 10.1016/j.jacc.2012.07.040 23040575

15. Leschke M, Waliszewski M, Pons M, Champin S, Nait Saidi L, Mok Heang T, et al. A Thin strut bare metal stents in patients with atrial fibrillation: Is there still a need for BMS? Catheter Cardiovasc Interv. 2016;88:358–366. doi: 10.1002/ccd.26261 26650913

16. Mehran R, Chandrasekhar J, Davis S, Nathan S, Hill R, Hearne S, et al. Impact of Race and Ethnicity on the Clinical and Angiographic Characteristics, Social Determinants of Health, and 1-Year Outcomes After Everolimus-Eluting Coronary Stent Procedures in Women. Circ Cardiovasc Interv. 2019;12(4):e006918. doi: 10.1161/CIRCINTERVENTIONS.118.006918 30998393

17. Inohara T, Kohsaka S, Goto M, Furukawa Y, Fukushima M, Sakata R et al. Hypothesis of Long-Term Outcome after Coronary Revascularization in Japanese Patients Compared to Multiethnic Groups in the US. PLoS One. 2015;10:e0128252. doi: 10.1371/journal.pone.0128252 26023784

18. van Oeffelen AA, Rittersma S, Vaartjes I, Stronks K, Bots ML, Agyemang C. Are There Ethnic Inequalities in Revascularisation Procedure Rate after an ST-Elevation Myocardial Infarction? PLoS One. 2015;10(9):e0136415. doi: 10.1371/journal.pone.0136415 26368504

19. Tong J, Xiang WW, Ang AS, Sim WJ, Quah KH, Foo D, et al. Clinical outcomes of elderly South-East Asian patients in primary percutaneous coronary intervention for ST-elevation myocardial infarction. J Geriatr Cardiol. 2016;13:830–835. doi: 10.11909/j.issn.1671-5411.2016.10.001 27928224

20. Leschke M, Nhan VT, Waliszewski M, Palacios V, Horváth I, Ivanov VA, et al. The 'all comer' Coroflex Please drug-eluting stent registry in Europe and Asia—an overall and transcontinental assessment of the 10-month major adverse cardiac events. Indian Heart J. 2012;64:453–461. doi: 10.1016/j.ihj.2012.08.002 23102382

21. Reddon H, Patel Y, Turcotte M, Pigeyre M, Meyre D. Revisiting the evolutionary origins of obesity: lazy versus peppy-thrifty genotype hypothesis. Obes Rev. 2018;19:1525–1543. doi: 10.1111/obr.12742 30261552

22. Hickman PE, Lindahl B, Cullen L, Koerbin G, Tate J, Potter JM. Decision limits and the reporting of cardiac troponin: Meeting the needs of both the cardiologist and the ED physician. Crit Rev Clin Lab Sci. 2015;52:28–44. doi: 10.3109/10408363.2014.972497 25397345

23. Pepe M, Sardella G, Stefanini GG, Corcione N, Nestola PL, Morello A, et al. Impact of Insulin-Treated and Noninsulin-Treated Diabetes Mellitus in All-Comer Patients Undergoing Percutaneous Coronary Interventions With Polymer-Free Biolimus-Eluting Stent (from the RUDI-FREE Registry). Am J Cardiol. 2019 Nov 15;124(10):1518–1527. doi: 10.1016/j.amjcard.2019.08.015 31547997

Článek vyšel v časopise


2020 Číslo 1
Nejčtenější tento týden